Neothetics Company Profile (NASDAQ:NEOT)

About Neothetics (NASDAQ:NEOT)

Neothetics logoNeothetics, Inc. is a clinical-stage specialty pharmaceutical company, which develops therapeutics. The Company focuses on localized fat reduction and body contouring. It focuses on the development of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients. LIPO-202 is a first-in-class injectable formulation of the long-acting Beta2-adrenergic receptor agonist, and salmeterol xinafoate, which is an active ingredient in the United States Food and Drug Administration inhaled products, such as SEREVENT DISKUS, ADVAIR HFA and ADVAIR DISKUS. The Company is developing a product candidate, LIPO-102, an injectable form of a combination of salmeterol xinafoate and fluticasone propionate. LIPO-102 is indicated for the treatment of the orphan indication of symptomatic exophthalmos, or protrusion of the eye from the orbit, associated with thyroid-related eye disease caused by the expansion of fat and muscle behind the eye.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NEOT
  • CUSIP: N/A
  • Web: www.neothetics.com
Capitalization:
  • Market Cap: $4.99 million
  • Outstanding Shares: 13,831,000
Average Prices:
  • 50 Day Moving Avg: $0.38
  • 200 Day Moving Avg: $1.27
  • 52 Week Range: $0.30 - $2.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.86
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.47 per share
  • Price / Book: 0.77
Profitability:
  • EBIDTA: ($9,540,000.00)
  • Return on Equity: -98.61%
  • Return on Assets: -86.58%
Debt:
  • Current Ratio: 4.76%
  • Quick Ratio: 4.76%
Misc:
  • Average Volume: 931,211 shs.
  • Beta: 2.33
  • Short Ratio: 0.61
 

Frequently Asked Questions for Neothetics (NASDAQ:NEOT)

What is Neothetics' stock symbol?

Neothetics trades on the NASDAQ under the ticker symbol "NEOT."

How were Neothetics' earnings last quarter?

Neothetics, Inc. (NASDAQ:NEOT) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). View Neothetics' Earnings History.

When will Neothetics make its next earnings announcement?

Neothetics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Neothetics.

Are investors shorting Neothetics?

Neothetics saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 1,280,217 shares, an increase of 48.6% from the July 31st total of 861,273 shares. Based on an average daily volume of 902,529 shares, the days-to-cover ratio is currently 1.4 days. Currently, 14.6% of the shares of the company are short sold.

Who are some of Neothetics' key competitors?

Who are Neothetics' key executives?

Neothetics' management team includes the folowing people:

  • Susan A. Knudson, Chief Financial Officer
  • Maria Feldman, Vice President, Clinical Operations, Regulatory Affairs and Quality Assurance
  • Kim P. Kamdar Ph.D., Lead Independent Director
  • Martha J. Demski, Independent Director
  • Maxim Gorbachev, Independent Director
  • Jeffrey M. Nugent, Independent Director

When did Neothetics IPO?

(NEOT) raised $60 million in an initial public offering (IPO) on Thursday, November 20th 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Piper Jaffray and Guggenheim Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

Who owns Neothetics stock?

Neothetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu KCG Holdings LLC (2.01%). Company insiders that own Neothetics stock include Alta Partners Viii, LP, Kenneth W Locke and Susan A Knudson. View Institutional Ownership Trends for Neothetics.

Who bought Neothetics stock? Who is buying Neothetics stock?

Neothetics' stock was purchased by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC. View Insider Buying and Selling for Neothetics.

How do I buy Neothetics stock?

Shares of Neothetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neothetics' stock price today?

One share of Neothetics stock can currently be purchased for approximately $0.36.


MarketBeat Community Rating for Neothetics (NASDAQ NEOT)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  27 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  45
MarketBeat's community ratings are surveys of what our community members think about Neothetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Neothetics (NASDAQ:NEOT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Neothetics (NASDAQ:NEOT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/15/2015Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/15/2015Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
11/2/2015GuggenheimReiterated RatingBuy$16.00N/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Neothetics (NASDAQ:NEOT)
Earnings by Quarter for Neothetics (NASDAQ:NEOT)
Earnings History by Quarter for Neothetics (NASDAQ NEOT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017N/AView Earnings Details
8/10/2017Q2 2017($0.20)($0.20)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.19)($0.22)ViewN/AView Earnings Details
3/23/2017Q4 2016($0.20)($0.14)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.31)($0.17)ViewN/AView Earnings Details
8/11/2016Q2($0.40)($0.19)ViewN/AView Earnings Details
5/12/2016Q1($0.44)ViewN/AView Earnings Details
3/29/2016Q4($1.14)($0.69)ViewN/AView Earnings Details
11/12/2015Q315($0.84)($1.26)ViewN/AView Earnings Details
8/13/2015Q215($1.14)($0.69)ViewN/AView Earnings Details
5/14/2015Q115($0.93)($0.50)ViewN/AView Earnings Details
3/26/2015Q414($0.32)($0.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neothetics (NASDAQ:NEOT)
Current Year EPS Consensus Estimate: $-0.610 EPS
Next Year EPS Consensus Estimate: $-0.420 EPS

Dividends

Dividend History for Neothetics (NASDAQ:NEOT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neothetics (NASDAQ:NEOT)
Insider Ownership Percentage: 39.20%
Institutional Ownership Percentage: 4.65%
Insider Trades by Quarter for Neothetics (NASDAQ:NEOT)
Insider Trades by Quarter for Neothetics (NASDAQ:NEOT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/30/2015Alta Partners Viii, L.P.InsiderSell797,987$1.51$1,204,960.37View SEC Filing  
12/29/2015Alta Partners Viii, L.P.Major ShareholderSell493,654$1.53$755,290.62View SEC Filing  
12/28/2015Alta Partners Viii, L.P.Major ShareholderSell54,333$1.59$86,389.47View SEC Filing  
12/17/2015Kenneth W. LockeInsiderSell598$1.26$753.48View SEC Filing  
12/17/2015Susan A. KnudsonCFOSell1,005$1.26$1,266.30View SEC Filing  
12/15/2015Alta Partners Viii, L.P.Major ShareholderSell529,261$1.44$762,135.84View SEC Filing  
11/18/2015Kenneth W. LockeinsiderSell6,098$8.30$50,613.40View SEC Filing  
9/18/2015Christopher KemmererVPSell1,000$12.20$12,200.00View SEC Filing  
9/1/2015Susan A. KnudsonCFOSell3,000$11.33$33,990.00View SEC Filing  
3/19/2015George W MahaffeyCEOBuy1,000$7.76$7,760.00View SEC Filing  
11/25/2014Daniel JanneyDirectorSell149,286$14.00$2,090,004.00View SEC Filing  
11/25/2014Rmi Investments S.A.R.L.Major ShareholderBuy70,000$14.00$980,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neothetics (NASDAQ:NEOT)
Latest Headlines for Neothetics (NASDAQ:NEOT)
Source:
DateHeadline
finance.yahoo.com logoNeothetics Inc (NEOT): How Does It Impact Your Portfolio?
finance.yahoo.com - September 19 at 2:38 AM
americanbankingnews.com logoShort Interest in Neothetics, Inc. (NEOT) Increases By 48.6%
www.americanbankingnews.com - August 28 at 1:20 AM
reuters.com logoBRIEF-Neothetics posts Q2 loss per share $0.20
www.reuters.com - August 12 at 8:14 PM
americanbankingnews.com logoNeothetics, Inc. (NEOT) Releases Earnings Results, Meets Estimates
www.americanbankingnews.com - August 11 at 7:54 PM
finance.yahoo.com logoNeothetics Provides Business Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 11 at 6:53 AM
finance.yahoo.com logoNeothetics Announces Review of Strategic Alternatives
finance.yahoo.com - July 11 at 3:27 AM
marketwatch.com logoNeothetics stock plummets 66% on news of negative results for fat-reduction drug
www.marketwatch.com - June 27 at 6:53 PM
rttnews.com logoNeothetics Inc. (NEOT) Sank To A 10-Month Low After Phase 2 Study Failed
www.rttnews.com - June 27 at 6:53 PM
finance.yahoo.com logoNeothetics Announces Top-Line Results for Phase 2 Proof-of-Concept Study of LIPO-202 for the Reduction of Submental Subcutaneous Fat
finance.yahoo.com - June 26 at 8:49 AM
finance.yahoo.com logoNeothetics stock halted on news of negative results for fat-reduction drug
finance.yahoo.com - June 26 at 8:49 AM
americanbankingnews.com logoNeothetics Inc (NEOT) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS
www.americanbankingnews.com - May 12 at 2:46 PM
finance.yahoo.com logoNeothetics Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 9:28 AM
finance.yahoo.com logoNeothetics to Provide a Business Update and Release First Quarter 2017 Financial Results Thursday, May 11th, 2017
finance.yahoo.com - May 4 at 11:25 AM
americanbankingnews.com logoNeothetics (NEOT) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - April 13 at 6:15 PM
finance.yahoo.com logoNeothetics Posts Solid Win on Patent Approval
finance.yahoo.com - April 7 at 7:13 PM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - April 3 at 6:07 PM
biz.yahoo.com logoQ4 2016 Neothetics Inc Earnings Release - Before Market Open
us.rd.yahoo.com - March 23 at 7:18 PM
us.rd.yahoo.com logoNeothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results
us.rd.yahoo.com - March 23 at 7:18 PM
finance.yahoo.com logoNeothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat
finance.yahoo.com - March 20 at 10:01 AM
finance.yahoo.com logoNeothetics to Provide a Business Update and Release Fourth Quarter 2016 Financial Results Thursday, March 23, 2017
finance.yahoo.com - March 16 at 9:04 AM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 7 at 6:37 PM
streetinsider.com logoForm SC 13G/A Neothetics, Inc. Filed by: DRILL CRAIG A
www.streetinsider.com - January 6 at 7:29 PM
zacks.com logoNeothetics (NEOT) Begins Phase II Study on Lead Candidate
www.zacks.com - December 28 at 10:05 AM
streetinsider.com logoNeothetics (NEOT) Phase 2 Proof of Concept Trial for LIPO-202 Initiated for Double Chin
www.streetinsider.com - December 24 at 6:18 PM
baystreet.ca logoNeothetics (NEOT) Leaped as New Drug Trial Commences
www.baystreet.ca - December 23 at 8:17 PM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement
biz.yahoo.com - September 23 at 5:55 PM
nasdaq.com logoNeothetics Provides Business Update and Reports Second Quarter 2016 Financial Results
www.nasdaq.com - August 11 at 9:37 AM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
biz.yahoo.com - June 17 at 8:01 AM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
biz.yahoo.com - June 6 at 8:01 AM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - May 12 at 8:01 AM
biz.yahoo.com logoQ1 2016 Neothetics Inc Earnings Release - Before Market Open
biz.yahoo.com - May 12 at 7:07 AM
finance.yahoo.com logoStocks To Watch: Investors Are Considering These on Monday April 25th
finance.yahoo.com - April 25 at 11:30 AM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Principal
biz.yahoo.com - February 18 at 4:08 PM
finance.yahoo.com logoNeothetics Announces Leadership Change and Preliminary Update on LIPO-202
finance.yahoo.com - February 18 at 4:00 PM
247wallst.com logoWhy Neothetics Is Getting Destroyed
247wallst.com - December 15 at 1:15 PM
finance.yahoo.com logoBreaking: This Biotech Just Got Blown Up on a Late Stage Trial
finance.yahoo.com - December 14 at 5:54 PM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - December 14 at 5:02 PM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events
biz.yahoo.com - December 10 at 4:39 PM
finance.yahoo.com logoNEOTHETICS, INC. Financials
finance.yahoo.com - December 8 at 1:17 PM
biz.yahoo.com logoNEOTHETICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - December 1 at 5:21 PM

Social

Chart

Neothetics (NEOT) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff